NGS-based RNA sequencing market seen reaching $12.73 billion by 2030

The Business Research Company says the NGS-based RNA-sequencing market will rise from $4.2 billion in 2025 to $12.73 billion by 2030, driven by precision medicine, pharmaceutical research and broader clinical use. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through the forecast period.

Why it matters: - NGS-based RNA sequencing is becoming a core tool for gene-expression analysis, drug discovery and precision medicine. - The market’s projected jump to $12.73 billion by 2030 signals rising demand for faster, more scalable molecular analysis across research and clinical settings. - Pharmaceutical spending and research activity are helping push adoption of advanced sequencing tools.

What happened: - The Business Research Company released a market report on NGS-based RNA sequencing on August 19, 2026. - The report estimates the market will grow from $4.2 billion in 2025 to $5.27 billion in 2026. - The report projects the market will reach $12.73 billion by 2030. - The company said the market is expected to grow at a 25.3% CAGR from 2025 to 2026 and 24.7% through 2030. - The report includes a free sample and the full market report.

The details: - NGS-based RNA sequencing identifies and quantifies RNA molecules in a biological sample at a specific time using next-generation sequencing. - The method supports massively parallel sequencing. - The technology offers high throughput, scalability and speed. - The report says the market’s recent growth has been driven by expanding genomic research, lower sequencing costs, broader use in academic settings, advanced sequencing platforms and stronger bioinformatics tools. - The report says future growth will be supported by wider clinical adoption, more precision medicine investment, higher pharmaceutical research activity, stronger demand for integrated data analysis and more multi-omics studies. - The report highlights rising use of high-throughput RNA sequencing, single-cell RNA sequencing, cloud-based bioinformatics platforms, transcriptomics in personalized medicine and data systems built for accuracy and scale. - North America held the largest market share in 2025. - Asia-Pacific is expected to post the fastest growth rate during the forecast period. - The analysis also covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

Between the lines: - The forecast suggests RNA sequencing is moving from a specialized research tool toward broader routine use in drug development and clinical workflows. - Pharmaceutical companies are likely to remain a major demand source because gene-expression data can help identify targets, assess efficacy and study disease mechanisms. - CMS reported prescription drug spending rose 11.4% in 2023 to $449.7 billion, up from 7.8% growth in 2022, underscoring the scale of drug-sector activity feeding demand for molecular tools. - The report’s emphasis on cloud bioinformatics and data scalability points to a market where software and analytics are becoming as important as sequencing hardware.

What's next: - The market will likely be shaped by adoption in precision medicine, continued pharmaceutical R&D and expanding single-cell and multi-omics applications. - Regional growth may increasingly shift toward Asia-Pacific as clinical and research infrastructure expands. - The Business Research Company said its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel-based forecasting dashboards, market hotspot infographics and updated trend analysis.

The bottom line: - NGS-based RNA sequencing is on track for rapid expansion, with the biggest gains tied to clinical adoption, pharmaceutical demand and data-driven genomics workflows.